Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * ARCH Venture Fund XIII, L.P. 2. Date of Event Requiring Statement (Month/Day/Year) 07/25/2025 3. Issuer Name and Ticker or Trading Symbol Lyell Immunopharma, Inc. [LYEL] (Last) (First) (Middle) 8755 W. HIGGINS ROAD, SUITE 1025, 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) CHICAGO, IL 60631 6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 938,438(1) I By: ARCH Venture Fund XIII, L.P.(2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ARCH Venture Fund XIII, L.P. 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631		X
ARCH Venture Partners XIII, L.P. 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631		X
ARCH Venture Partners XIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631		X
CRANDELL KEITH C/O ARCH VENTURE PARTNERS IX, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631		X
NELSEN ROBERT 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631		X
Burow Kristina 8755 W. HIGGINS ROAD,SUITE 1025 CHICAGO, IL 60631		X
GILLIS STEVEN C/O ARCH VENTURE PARTNERS 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631		X
BERNS PAUL L 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631		X

Signatures

ARCH Venture Partners XIII, LLC, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director		07/29/2025
**Signature of Reporting Person		Date
ARCH Venture Partners XIII, L.P., By: ARCH Venture Partners XIII, LLC, its General Partner, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director		07/29/2025
**Signature of Reporting Person		Date
ARCH Venture Fund XIII, L.P., By: ARCH Venture Partners XIII, L.P., its General Partner, By: ARCH Venture Partners XIII, LLC, its General Partner, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director		07/29/2025
**Signature of Reporting Person		Date
Keith Crandell, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact		07/29/2025
**Signature of Reporting Person		Date
Robert Nelsen, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact		07/29/2025
**Signature of Reporting Person		Date
Kristina Burow, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact		07/29/2025
**Signature of Reporting Person		Date
Steven Gillis, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact		07/29/2025
**Signature of Reporting Person		Date
Paul Berns, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact		07/29/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	These shares were purchased on July 25, 2025 pursuant to a securities purchase agreement dated July 24, 2025 at a price per share of $13.32.
(2)	These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.